# EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

> **NCT03683524** · PHASE4 · COMPLETED · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 96 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).
- **DRUG:** Current ART

## Key facts

- **NCT ID:** NCT03683524
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-08-10
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03683524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03683524, "EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03683524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*